Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer

J Thorac Oncol. 2017 May;12(5):e41-e43. doi: 10.1016/j.jtho.2016.12.015. Epub 2016 Dec 23.

Authors

Affiliations

¹ Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. Electronic address: yusui@east.ncc.go.jp.
² Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
³ Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan.

PMID: 28017788
DOI: 10.1016/j.jtho.2016.12.015

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Carcinoma, Non-Small-Cell Lung / blood*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Diabetes Mellitus, Type 1 / blood
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / genetics
Diabetes Mellitus, Type 1 / immunology
Female
HLA Antigens / genetics*
Haplotypes
Humans
Lung Neoplasms / blood*
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Middle Aged
Nivolumab

Substances

Antibodies, Monoclonal
Antineoplastic Agents
HLA Antigens
Nivolumab